INTRODUCTION
Waldenström Macroglobulinemia (WM) is a low-grade lymphoplasmacytic lymphoma characterized by the presence of an IgM monoclonal protein in the serum (1) (2) (3) (4) .
Patients typically present with symptoms related to cytopenias mainly anemia or symptoms related to hyperviscosity (1) (2) (3) (4) . Many patients have an indolent disease with a median overall survival of 5 years; however, some patients with high-risk features, only have a 5-year survival of 36% (2, 3, 5, 6) .
Standard therapeutic agents currently used in the treatment of this disease include alkylating agents, rituximab, nucleoside analogues and stem cell transplantation.
Many new agents have been recently tested in WM including bortezomib, lenalidomide, perifosine, everolimus, and bendamustine. However, most patients show disease relapse post-treatment with these agents or have significant toxicities including prolonged myelosuppression or neuropathy. Therefore, there is an urgent need to develop therapies that are beneficial for this unique population of patients.
Epigenetic alterations including methylation and histone acetylation are commonly deregulated in most cancers (7, 8) . Histone acetylation is regulated by a tight balance For personal use only. on July 16, 2017. by guest www.bloodjournal.org From between histone deacetylase (HDAC) and histone acetyl transferases (HATs) (9) . This balance is disrupted in many malignancies leading to increased expression of HDACs and a more open chromatin structure that induces activation of gene transcription.
We, and others have shown that miRNAs are also deregulated in WM (10, 11) . Our data indicated that aberrant increased expression of miRNA-206 and reduced expression of miRNA-9* leads to activation of HDACs in WM. Our data showed that HDACs and HATs are unbalanced in WM, with a decreased acetylated-histone-H3
and -H4, and increased HDAC activity in primary tumor cells compared to their normal cellular counterpart. Using the novel cinnamic hydroxamic acid HDAC inhibitor panobinostat (LBH589, Novartis, MA), we confirmed that this agent induces significant cytotoxicity in vitro and in vivo in WM cells.
Based on these promising preclinical studies, we designed a phase II clinical trial of single agent panobinostat to examine the response rate, toxicity, and progression-free survival in patients with relapsed or relapsed/refractory WM.
MATERIALS AND METHODS

Eligibility
Study participants were at least 18 years of age and had symptomatic disease requiring therapy for WM according to the consensus recommendations for WM (12) .
Patients had measurable monoclonal IgM immunoglobulin concentration on serum electrophoresis and IgM immunoglobulin protein twice the upper limit of normal by For personal use only. on July 16, 2017. by guest www.bloodjournal.org From nephlometry and evidence of lymphoplasmacytic cells in the bone marrow. Patients who had at least one previous therapy for WM and were relapsed or refractory were eligible. Any number of prior therapy was permissible. Patients must have had symptomatic disease requiring therapy to be entered on the study. Eligibility criteria also included a serum concentration of AST or ALT < 3 times the upper limit of the normal range, a serum total bilirubin <2 mg/dL, a measured creatinine <3.5 times the upper limit of the normal range, a platelet count of ≥75,000/mL, and an absolute neutrophil count of at least ANC ≥ 1.0 x 10 9 /L. All patients gave written informed consent before entering the study, which was performed in accordance with the Declaration of Helsinki; approval was obtained from the institutional review board at each of the participating centers, (clinical trials.gov, NCT00936611).
Study Design and Treatment
Patients received single agent oral panobinostat 30 mg three days a week (Mondays, Wednesdays and Fridays). A cycle was 28 days. Patients with progressive disease after two cycles were taken off therapy. Patients with stable or responsive disease continued on therapy, (See Consort diagram). Restaging with a bone marrow biopsy and CT scans were performed at the end of cycle 6. Dose modifications for attributable toxicities were allowed. Panobinostat could be reduced to 25 mg, 20 mg three times a week every week, or 20 mg three times a week every other week. No dose re-escalation was allowed. Dexamethasone was not allowed on this protocol. The protocol was amended because of concerns of toxicity to For personal use only. on July 16, 2017. by guest www.bloodjournal.org From allow a starting dose of 25 mg; 12/36 (33%) patients were enrolled on the 25 mg dose.
Efficacy and Safety Assessments
Tumor assessment was performed using the consensus panel recommendations (13) .
Patients were assessed every 28 days during the 6 cycles of therapy and every 3 months thereafter. Patients who came off therapy were monitored every 3 months until they progressed, were treated with another therapy, or died.
Response was calculated from the M spike measurement (or IgM measurement) of cycle 1 day 1 prior to therapy. Response was determined based on the IWMG response criteria (13) including CT scan and bone marrow assessment. All responses were confirmed. PR was assessed as patients having 50% reduction in pathological lymph nodes. Adverse events were assessed at each visit and graded according to the National Cancer Institute Common Toxicity Criteria (version 3.0) from the first dose until 30 days after the last dose of therapy.
Statistical Analysis
The primary endpoint was the overall response rate (defined as MR or better) and secondary endpoints included safety, duration of response (DR), time to progression (TTP) and progression-free survival (PFS). This study used a two-stage design ( Comparisons between groups were performed using Fisher's exact test for binary endpoints and Wilcoxon rank sum test for continuous endpoints. Median time to event endpoints was estimated using the Kaplan-Meier method. Duration of response was measured from response to first PD or death, censored at the date patients were last known to be event-free and alive for those who have not failed. Time to progression (TTP), progression-free survival (PFS) and event free survival are measured from the time of treatment initiation to event (PD for TTP, PD or death for PFS, PD, death or non-protocol therapy for EFS). Patients without the event are censored at the date they were last known to be progression-free for TTP, and progression-free and alive for PFS and EFS. In addition, patients who start non-protocol therapy prior to progression are censored at the date of non-protocol therapy initiation for TTP and PFS and are events for EFS. All P-values are two-sided. Statistical analyses were performed using SAS statistical software (version 9.2, SAS Institute).
Correlative studies
Peripheral blood mononuclear cells were obtained from patients prior to therapy (at screening or on day 1 cycle 1), n=11 samples. In addition, samples were also For personal use only. on July 16, 2017. by guest www.bloodjournal.org From obtained after cycle 3 or cycle 6 on some patients (n=3). The level of acetylated Histone 3 was measured using ELISA assay (Cell Signaling, MA) in these samples as previously described (10) .
Bone marrow biopsies from 14 patients at pre-treatment or after therapy were fixed in Zenker's formalin, embedded in paraffin blocks, and sectioned. Sections were stained for CD20, kappa and lambda light chains (Cell Signaling Technology Inc, MA).
RESULTS
Patients and Treatment
From July 2009 to March 2011, 39 patients were enrolled; 36 started on active therapy in 2 centers, and 3 patients were found to be ineligible and were not initiated on therapy ( Figure 1 , Consort Diagram). Table 1 At the time of this analysis, 8 patients remain on study follow up (7 on active therapy), and the remaining 28 patients are off study due to progressive disease in 3 (11%), new systemic therapy in 22 (61%), patients lost to follow up in 1 (3%) and patient withdrawal from study in 2 (5%).
Efficacy
Using the uniform WM response criteria (13) that includes monoclonal M spike and CT scans for measuring organ and lymph node involvement, the following responses were observed: Of the 36 patients, 8 achieved a partial response (PR) (22%), and 9 achieved minor response (MR) (25%), with an overall response rate of 17/36 (47% (90% CI, 33-62), (Table 2) . Stable disease was achieved in 18 (50%) of the patients and 1 (3%) patient was unevaluable because he did not complete the first cycle and did not have M spike measurements post initiation of therapy. The median time to first response (N=17) was 1.7 months (0.9-1.8) and time to best response (N=17) was 1.8 months (1.7-3.2). The duration of response (MR or better) was 18.9 months (4.8, -).
Response using the monoclonal protein M spike level was as follows: 1 patient achieved a very good partial remission (VGPR) (3%), 10 patients achieved PR (27%), Figure 2 shows the maximum percent change from baseline in IgM over all cycles among all patients.
Bone marrow biopsies were performed, and results were available before and after therapy (after at least 6 cycles of therapy) in 20 (56%) patients. Of these 20 patients, 12/20 (60%) patients showed reduction in the % involvement of bone marrow after therapy, with a median % decrease of 63% (range, 20-94% decrease). These patients showed MR or better in 17/20 (85%) patients, and 3 patients showed stable disease by response criteria. Among the other 8 patients with no change in the bone marrow involvement or increase in BM involvement, the median % increase was 11%, with a range from 0-300%. The increase in 300% was in a patient with a percent increase from 5% to 20% in his pre and post-treatment samples respectively. The responses in these 8 patients included 2 PR, 3MR, and 3 stable disease by response criteria.
Given that 23 patients were initiated on therapy at 30 mg dosing and then the dose was reduced because of toxicity and another 12 patients were initiated on therapy at 25 mg starting dose, we reported on the response rates of the patients initiated on 30 
Time to progression and progression-free survival
After a median follow up of 7.7 months (90%CI 6.8-9.5), 24 patients have progressed; of these, 1 subsequently died and 14 are alive. Among the other 12, 4 started a new therapy and one patient died without documented disease assessment of progression, measured as 25% progression in the paraprotein.
The two deaths occurred off therapy and after receiving subsequent therapy. Both patients died with large cell transformation and progressive disease. One patient received 16 cycles of therapy and then showed progression and went on to another therapy. The patient then developed infections and large cell transformation and died 6 months after being on panobinostat. The second patient received 2 cycles of therapy and then withdrew consent. The patient had another therapy and also showed large cell transformation and died 7 months after being on the clinical trial.
The median duration of response (MR or better, n=17) was 6.9 months (90%CI 3.1,-18.9), Figure 3A . The median time to progression (TTP) and progression free survival (PFS) were similar in the 36 patients who had follow up and was 6.6 months (90%CI For personal use only. on July 16, 2017. by guest www.bloodjournal.org From 5.5,14.8), Figure 3B . In the TTP and PFS analysis, patients who started non-protocol therapy prior to progression (n=4) were censored at the initiation of non-protocol treatment. For the EFS analysis, in which the initiation of non-protocol therapy is counted as an event, the median EFS time is 5.8 (90% CI 4.6-7.7) months, Figure 3C .
The estimated 1-year event free rate was 31% (90% CI 19-44%). The estimated event free rate at 2 years was 17% (90% CI, 7%-29%).
Safety
A summary of all toxicities related to therapy is shown in Table 3A . The most common grade 3 and 4 therapy related adverse events included thrombocytopenia in 67%, neutropenia in 36%, anemia in 28%, and leukopenia in 22%, fatigue in 11% and syncope in 6%. Grade 1 and 2 diarrhea occurred in 58%, nausea and anorexia in 44%, taste disturbance in 28%, lower extremity edema in 22%, weight loss in 22%, dizziness in 19%, dyspnea in 19%, and alopecia in 17%. Pneumonitis occurred in 5 patients, 4 grade 1 and 1 grade 2 toxicity. All of those were observed incidentally with CT scans performed during staging studies in follow up during therapy. Pneumonitis was treated with tapering doses of steroids as well as withholding therapy and reinitiating it at a dose reduction.
Grade 3 and 4 toxicities observed in patients who were initiated at 30 mg (N=23) or in those initiated at dose 25 mg (N=13) is shown in Table 3B . There was no difference in the rate of Grade 3 and 4 toxicities observed in these two groups.
Translational studies
For personal use only. on July 16, 2017. by guest www.bloodjournal.org From
The degree of involvement (% involvement) observed in bone marrow biopsies pre and post-treatment in patients who achieved MR or better to therapy is shown in Figure 4A . The level of acetylated H3 in the peripheral blood mononuclear cells is shown in Figure 4B . The numbers were too small to perform correlative studies with response to therapy. Interestingly, we observed an increase in the level of acetylated H3 post-therapy in post-treatment samples, Figure 4C . 
This study shows a response rate of MR or better in 47% of patients with 22% partial remissions. Response by paraprotein M spike level included response of MR or better of 55% and PR or better of 30% including 1 VGPR, 10 PR, 9 MR, and 1 unevaluable.
Other studies using novel agents in a similar population of relapsed or refractory WM have shown responses of MR or better of 30 to 50% using rituximab, 35% using perifosine, 70% using everolimus, and 26-80% using bortezomib. Therefore, the response rate of 47% of single agent panobinostat indicates that indeed this class of agents is highly active in patients with this low-grade lymphoma.
The response rate of panobinostat in other lymphomas and plasma cell dyscrasias varies (18) (19) (20) (21) . It is significantly high in Hodgkin lymphoma with 30-60% responses and minimal to no responses of single agent panobinostat in Multiple Myeloma(22).
However, significant responses were observed in combinations of panobinostat and bortezomib in Multiple Myeloma (23, 24) . Therefore, future studies using panobinostat and bortezomib or other proteasome inhibitors can lead to high responses in patients with WM. The progression free survival (PFS) in this trial was 6.6 months. The median PFS survival for bortezomib was 6.6 months in the Waldenstrom's Macroglobulinemia Clinical Trials Group study in a similar patient population (25).
This study is relatively small and was performed in only 2 centers, one academic and one community-based. The younger median age of 62 (compared to median age of 63-65 in other reported studies) and the relatively lower high-risk ISS of 19% (compared to 35% in newly diagnosed patients) may be due to referral bias of these Figure 4C 
